GNTA vs. CADL, IPHA, IVVD, CHRS, GLUE, ELEV, SCLX, CRBU, ZURA, and CMPX
Should you be buying Genenta Science stock or one of its competitors? The main competitors of Genenta Science include Candel Therapeutics (CADL), Innate Pharma (IPHA), Invivyd (IVVD), Coherus BioSciences (CHRS), Monte Rosa Therapeutics (GLUE), Elevation Oncology (ELEV), Scilex (SCLX), Caribou Biosciences (CRBU), Zura Bio (ZURA), and Compass Therapeutics (CMPX). These companies are all part of the "biological products, except diagnostic" industry.
Candel Therapeutics (NASDAQ:CADL) and Genenta Science (NASDAQ:GNTA) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their earnings, institutional ownership, profitability, community ranking, media sentiment, analyst recommendations, risk, dividends and valuation.
13.9% of Candel Therapeutics shares are owned by institutional investors. Comparatively, 15.1% of Genenta Science shares are owned by institutional investors. 41.6% of Candel Therapeutics shares are owned by insiders. Comparatively, 29.0% of Genenta Science shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.
Candel Therapeutics presently has a consensus target price of $11.00, suggesting a potential upside of 53.85%. Genenta Science has a consensus target price of $25.00, suggesting a potential upside of 657.58%. Given Candel Therapeutics' higher probable upside, analysts clearly believe Genenta Science is more favorable than Candel Therapeutics.
Candel Therapeutics received 2 more outperform votes than Genenta Science when rated by MarketBeat users. However, 85.71% of users gave Genenta Science an outperform vote while only 50.00% of users gave Candel Therapeutics an outperform vote.
Candel Therapeutics' return on equity of 0.00% beat Genenta Science's return on equity.
Genenta Science has lower revenue, but higher earnings than Candel Therapeutics.
Candel Therapeutics has a beta of -0.84, indicating that its stock price is 184% less volatile than the S&P 500. Comparatively, Genenta Science has a beta of 0.77, indicating that its stock price is 23% less volatile than the S&P 500.
In the previous week, Genenta Science's average media sentiment score of 1.92 beat Candel Therapeutics' score of 0.00 indicating that Candel Therapeutics is being referred to more favorably in the media.
Summary
Genenta Science beats Candel Therapeutics on 8 of the 12 factors compared between the two stocks.
Get Genenta Science News Delivered to You Automatically
Sign up to receive the latest news and ratings for GNTA and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding GNTA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Genenta Science Competitors List
Related Companies and Tools
